In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...

“Weight-loss methods, whether with pharmacotherapy or surgery, have to be mindful to avoid inducing these complications,” ...

Cholestatic liver diseases comprise a heterogeneous group of disorders characterized by impaired bile formation or flow, ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal ...

New data links the liver receptor GPR110 to sex-specific progression of metabolic dysfunction-associated steatohepatitis.

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Right now, patients with obesity and cirrhosis ...

A Rutgers-led study in Science Advances found low-protein diets slowed liver tumor growth and cancer death in mice, ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Steatotic liver disease (commonly called fatty liver disease) progresses silently. Even in the absence of noticeable symptoms ...

New analysis shows alcohol-related liver disease remains a major cause of cirrhosis and liver death. Read more.